SillaJen Inc
215600
Company Profile
Business description
SillaJen Inc is a Korean based biotechnology company focused on engineering and developing cancer treatment cells. The company along with its subsidiary SillaJen Biotherapeutics, Inc offers Pexa-Vec, an oncolytic virus with antibodies, and improved survival in a randomized trial to cure cancer; and JX929, an engineered vaccinia virus strain that acts on cancer cells by viral attack and subsequent cancer cell oncolysis. SillaJen operates its business activities in Korea and United States.
Contact
6F, 252, Geumjeong-ro, Geumjeong-gu
Busan46274
KORT: +82 515177550
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
45
Stocks News & Analysis
stocks
Ask the analyst: How reliant are Guzman shares on international growth?
A year on from Guzman’s IPO, I catch up with Johannes Faul to explore what is baked into GYG’s valuation.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,006.80 | 116.00 | 1.30% |
| CAC 40 | 7,822.67 | 0.67 | 0.01% |
| DAX 40 | 24,289.51 | 81.42 | -0.33% |
| Dow JONES (US) | 44,342.19 | 142.30 | -0.32% |
| FTSE 100 | 8,992.12 | 19.48 | 0.22% |
| HKSE | 24,825.66 | 326.71 | 1.33% |
| NASDAQ | 20,895.65 | 10.01 | 0.05% |
| Nikkei 225 | 39,819.11 | 82.08 | -0.21% |
| NZX 50 Index | 12,880.40 | 25.01 | -0.19% |
| S&P 500 | 6,296.79 | 0.57 | -0.01% |
| S&P/ASX 200 | 8,757.20 | 118.20 | 1.37% |
| SSE Composite Index | 3,534.48 | 17.66 | 0.50% |